CD274 and Merkel cell skin cancer: Clinical trials exploring the use of PD-1/PD-L1 immune checkpoint inhibitors in combating metastatic MCC have yielded promising results, but a substantial portion of MCC patients are unresponsive to these immunotherapies [7,8,9,10,11,12,13].